Nassif David W. 4
4 · Axovant Gene Therapies Ltd. · Filed Sep 24, 2019
Insider Transaction Report
Form 4
Nassif David W.
Principal Financial Officer
Transactions
- Award
Restricted Stock Units
2019-09-21+30,120→ 30,120 total→ Common Shares (30,120 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
- [F2]50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date.